- For US Healthcare Professionals
- Prescribing Information
- CARVYKTI® REMS
Overall Survivala5
OS IN CARTITUDE-1
- OS was a secondary endpoint in the CARTITUDE-1 trial and could not be statistically tested in the setting of a single-arm trial
- The statistical significance of OS is not known
- The data are presented here for descriptive purpose only
As of January 11, 2022, which was the data cutoff, 66 of the 97 patients who received cilta-cel infusion remain in the study. Thirty patients died and 1 withdrew from the study
CI=confidence interval; OS=overall survival; USPI=US Prescribing Information.
aBased on a median duration of follow-up of 27.7 months.5